This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

• Small-cap biotech Jaguar Health’s stock jumps as it launches treatment for a painful side effect of cancer treatment

  Business - MarketWatch - October 16
• 

  Bipolar disorder: how lithium as a treatment fell out of favour

  World - The Guardian - 4 days ago

• Vietnam waits for major upgrade to its $200 billion stock market

  Business - CNBC - October 28

• Biotech stock tumbles after unexplained 1,446% gain

  Business - MarketWatch - October 16

• Sage Therapeutics’ stock falls 4.7% as biotech unveils plan to cut 33% of workforce

  Business - MarketWatch - October 17

• Icahn Enterprises’ stock slides 14% as majority-owned CVR Energy suspends its dividend

  Business - MarketWatch - October 29
• 

  People with depression could administer brain stimulation at home, trial shows

  World - The Guardian - October 21

More from MarketWatch

• Trump’s ‘drill, baby, drill’ pledge may be a win-win for drivers and oil producers alike

  Business - MarketWatch - 23 minutes ago

• Why the stock market’s ‘Trump bump’ could become a ‘Trump dump’

  Business - MarketWatch - 28 minutes ago

• It’s not just election betting: Why one expert thinks prediction markets will become bigger than stocks

  Business - MarketWatch - 53 minutes ago

• I was invited to join a VIP investment club. It promoted bitcoin and other crypto — that’s when the trouble started.

  Business - MarketWatch - 1 hour ago

• ‘I’m 38 and completely broke’: I earn $50,000 a year. What professional degree will guarantee me six figures?

  Business - MarketWatch - 1 hour ago